Bioluminescent assays for cytochrome P450 enzymes

Methods in Molecular Biology

Volumn 987, Issue , 2013, Pages 1-9

  Auld, Douglas S ^a   Veith, Henrike ^b   Cali, James J ^c  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c PROMEGA CORPORATION   (United States)

Author keywords

Bioluminescent assays; Cytochrome P450; Enzyme assays

Indexed keywords

CYTOCHROME P450; FIREFLY LUCIFERASE;

ARTICLE; BIOLUMINESCENCE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME METABOLISM; ESTERIFICATION; PRIORITY JOURNAL; SCREENING; ANIMAL; HUMAN; LUMINESCENCE; METABOLISM; METHODOLOGY; PROTEIN BINDING;

ANIMALS; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME ASSAYS; HUMANS; LUMINESCENT MEASUREMENTS; PROTEIN BINDING;

EID: 84882974968     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-62703-321-3_1     Document Type: Article

References (14)

1. Wienkers LC, Heath TG (2005) Predicting in vivo drug interactions from in vitro drug discovery data. Nat Rev Drug Discov 4:825-833
2. Sobel M, Ma D, Cali JJ (2007) P450-Glo CYP3A4 biochemical and cell-based assays. Promega Notes 98:15-18
3. Veith H, Southall N, Huang R, James T, Fayne D, Artemenko N, Shen M, Inglese J, Austin CP, Lloyd DG, Auld DS (2009) Comprehensive characterization of cytochrome P450 isozyme selectivity across chemical libraries. Nat Biotechnol 27:1050-1055
4. Foti RS, Wahlstrom JL (2008) CYP2C19 inhibition: the impact of substrate probe selection on in vitro inhibition pro files. Drug Metab Dispos 36:523-528
5. Zlokarnik G, Grootenhuis PD, Watson JB (2005) High throughput P450 inhibition screens in early drug discovery. Drug Discov Today 10:1443-1450
6. Meisenheimer PL, Uyeda HT, Ma D, Sobol M, McDougall MG, Corona C, Simpson D, Klaubert DH, Cali JJ (2011) Proluciferin acetals as bioluminogenic substrates for cytochrome P450 activity and probes for CYP3A inhibition. Drug Metab Dispos 39:2403-2410
7. Cohen LH, Remley MJ, Raunig D, Vaz AD (2003) In vitro drug interactions of cytochrome p450: an evaluation of fluorogenic to conventional substrates. Drug Metab Dispos 31:1005-1015
8. Cali JJ, Ma D, Sobol M, Simpson DJ, Frackman S, Good TD, Daily WJ, Liu D (2006) Luminogenic cytochrome P450 assays. Expert Opin Drug Metab Toxicol 2:629-645
9. Auld DS, Zhang YQ, Southall NT, Rai G, Landsman M, Maclure J, Langevin D, Thomas CJ, Austin CP, Inglese J (2009) A basis for reduced chemical library inhibition of fire fly luciferase obtained from directed evolution. J Med Chem 52:1450-1458
10. Li AP (2009) Evaluation of luciferin-isopropyl acetal as a CYP3A4 substrate for human hepatocytes: effects of organic solvents, cytochrome P450 (P450) inhibitors, and P450 inducers. Drug Metab Dispos 37:1598-1603
11. Niles WD, Coassin PJ (2005) Piezo-and solenoid valve-based liquid dispensing for miniaturized assays. Assay Drug Dev Technol 3:189-202
12. Cleveland PH, Koutz PJ (2005) Nanoliter dispensing for uHTS using pin tools. Assay Drug Dev Technol 3:213-225
13. Niwa T, Murayama N, Yamazaki H (2008) Heterotropic cooperativity in oxidation mediated by cytochrome P450. Curr Drug Metab 9:453-462
14. Wang RW, Newton DJ, Liu N, Atkins WM, Lu AYH (2000) Human cytochrome P-450 3A4: in vitro drug-drug interactions are substratedependent. Drug Metab Dispos 28:360-366